After a decade-long biopharma boom cycle, companies in the sector around the world are now facing a funding crunch. During the deep freeze, they can’t afford to go it alone, some investors say.
“China biotechs need to work with the US, Europe and Japanese drug makers” to develop new drugs, partner at Qiming Capital Nisa Leung said during the Hong Kong Biotech Summit,...